Prostatic acid phosphatase (299-307)

Prostatic acid phosphatase (299-307) is a synthetic peptide fragment corresponding to amino acids 299 through 307 of the human prostatic acid phosphatase (PAP) protein. As a well-characterized epitope, this peptide holds significant value in immunological research, particularly in studies focused on prostate-specific antigens and tumor-associated proteins. The defined sequence allows for precise experimental manipulation, making it a preferred tool for investigating antigenic determinants, epitope mapping, and T-cell recognition related to prostate biology and oncology. Its biochemical stability and sequence specificity support a range of applications in both fundamental and translational research.

Epitope mapping: Researchers employ the 299-307 peptide fragment of prostatic acid phosphatase to identify and characterize antigenic regions within the full-length protein. By systematically analyzing the immune response to this defined sequence, scientists can delineate the specific amino acid residues involved in antibody recognition or T-cell activation. This approach is crucial for understanding the molecular basis of antigenicity, supporting the design of targeted immunoassays, and informing the development of peptide-based diagnostic reagents.

T-cell response studies: The defined sequence of this peptide enables detailed analysis of T-cell recognition and activation, especially in the context of prostate cancer immunology. Investigators use the fragment to stimulate peripheral blood mononuclear cells or T-cell lines in vitro, assessing their ability to recognize and respond to PAP-derived epitopes. Such studies are essential for elucidating the mechanisms of tumor antigen presentation, profiling patient-specific immune responses, and evaluating the immunogenic potential of prostate-associated antigens.

Peptide-based assay development: The prostatic acid phosphatase (299-307) peptide serves as a reliable standard or calibrator in the development of immunological assays, including ELISPOT, ELISA, and flow cytometry-based detection methods. Its sequence specificity and synthetic reproducibility facilitate the establishment of sensitive and quantitative assays for monitoring antigen-specific immune responses. These applications are particularly useful in research settings that require rigorous validation of assay performance and reproducibility.

Vaccine research models: In the field of cancer immunotherapy research, this peptide is often utilized as a model antigen for preclinical evaluation of peptide-based vaccine strategies. By incorporating the defined epitope into experimental vaccine constructs, scientists can systematically investigate parameters such as antigen processing, presentation, and the induction of cytotoxic T lymphocyte responses. These studies contribute to the rational design of next-generation immunotherapeutic approaches targeting prostate-associated antigens.

Peptide structure-function analysis: The availability of the 299-307 sequence allows for in-depth studies of structure-activity relationships within the prostatic acid phosphatase protein. Researchers can employ this fragment in binding assays, structural modeling, or mutational analyses to dissect the contribution of specific amino acid residues to antigenicity or protein-protein interactions. Such investigations enhance the broader understanding of PAP's functional domains and inform the design of optimized peptide analogs for research use.

1. An Open-label, Single-center, Safety and Efficacy Study of Eyelash Polygrowth Factor Serum

2. Glucagonlike peptide 2 analogue teduglutide: stimulation of proliferation but reduction of differentiation in human Caco-2 intestinal epithelial cells

3. Uncarboxylated osteocalcin decreases insulin-stimulated glucose uptake without affecting insulin signaling and regulators of mitochondrial biogenesis in myotubes

4. Investigating Potential Interactions Between Neurohypophyseal Peptides, their Drug Analogs, and Coagulation Factor VIII

5. Relatedness of antibodies to peptides containing homocitrulline or citrulline in patients with rheumatoid arthritis